Navigation Links
Oncomodulin in Medical News

Alseres Shares Begin Trading on the Pink Sheets OTC Market

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...

Alseres and BioAxone Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...

Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. F...

Alseres Pharmaceuticals, Inc. Announces $200,000 Financing

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. To Host Third Quarter 2008 Conference Call

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc.'s Chairman, Peter Savas, Reviews Company's Progress in its Annual Letter to Stockholders

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
Oncomodulin in Medical Technology

Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial

...n a Phase I/IIa clinical trial. The Company's research and pre- clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The company...
Oncomodulin in Biological Technology

Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Announces $1 Million Financing

...n a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Compan...

Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. Raises $5 Million

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights

...ies in which other of our regenerative technologies, including Inosine, oncomodulin and other compounds, are being tested in parallel in a series of models...ograms include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs direct...

Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...

Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting

...in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company...
Other Tags
(Date:8/27/2014)... 2014 With most forms of ... to use hearing protection when exposed to loud ... many different forms of hearing protection ... hearing protection training and devices for workers in ... The National Institute of Occupational Safety and Health ...
(Date:8/27/2014)... significantly improve musculoskeletal and overall health, and minimize or ... of the latest research on senior athletes (ages 65 ... Journal of the American Academy of Orthopaedic Surgeons ... aging causes an inevitable deterioration of the body and ... of related injuries such as sprains, strains and fractures; ...
(Date:8/27/2014)... August 27, 2014 For nearly two ... by the beloved mantra singers Deva Premal & Miten ... the release of their latest album in May, their ... in twenty-two countries around the globe, including Russia, Ukraine, ... and across Europe. With a new album and a ...
(Date:8/27/2014)... positive hospital blood culture samples are discarded every day ... skin germs instead of specific disease-causing bacteria. , ... clinicians may be able to use the resistance profiles ... patients with antibiotics appropriate to their ailment, Tel Aviv ... Alon of TAU,s Sackler Faculty of Medicine and the ...
(Date:8/27/2014)... New York (PRWEB) August 27, 2014 ... by Transparency Market Research "Ablation Technologies Market (Applications: ... Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - Global ... 2014 - 2020," the global ablation technologies market ... and is estimated to reach a market worth ...
Breaking Medicine News(10 mins):Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 2Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 3Health News:Lifetime of fitness: A fountain of youth for bone and joint health? 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 2Health News:Deva Premal & Miten's Mantras For Life Tour Announced 3Health News:'Junk' blood tests may offer life-saving information 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5
(Date:8/26/2014)... increased risk of autism among children of women ... the known increased risk associated with severe maternal ... publication in Molecular Psychiatry , investigators from ... a diagnosis of autism spectrum disorder was more ... during pregnancy than in those with no prenatal ...
(Date:8/26/2014)... the Ethical Treatment of Animals (PETA) and the PETA ... Prague this week at the 9th World Congress on ... original research on alternatives to the use of animals ... studies identifying problems with current laboratory oversight systems. , ... 24 to 28, 2014, PETA and PISC will present ...
(Date:8/26/2014)... , August 26, 2014 ... von Oxygen Forensic Passware Analyst bekannt, einem ... preisgekrönten Erfassungs- und Analysetools von Oxygen mit ...     Das neue Tool kombinierte ... einem einzigen nahtlosen Ablauf. Das neu hinzugekommene ...
Breaking Biology News(10 mins):Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3Oxygen Forensic Passware Analyst erfasst geschützte Mobilgerätedaten 2
Other Contents